MCM
KYNB

Manchester Capital Management’s Kyntra Bio KYNB Stock Holding History

Manchester Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-29
Closed -$39K – 586
2019
Q1 		$39K Buy
+29
New +$39.3K 0.01% 436

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Manchester Capital Management's KYNB Position: Q2 2019 in Review

Manchester Capital Management sold out of Kyntra Bio (KYNB) in Q2 2019, closing a stake of 29 shares — an estimated $39K sold.

Manchester Capital Management first reported a position in KYNB in Q1 2019 and held it in 1 quarter. The position peaked at $39K in Q1 2019. 190 funds tracked by Wall St. Rank hold KYNB as of Q2 2019.

  • Manchester Capital Management reported no remaining Kyntra Bio position as of Q2 2019 after selling out during the quarter.
  • Manchester Capital Management sold 29 Kyntra Bio shares in Q2 2019, an estimated $39K.
  • Manchester Capital Management first reported a position in Kyntra Bio in Q1 2019 and held it in 1 quarter.
  • Manchester Capital Management's Kyntra Bio position peaked at $39K in Q1 2019.
  • 190 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2019.

Based on Manchester Capital Management's 13F filing for Q2 2019, filed 5 Aug 2019.